Catinazzo Thomas 4
4 · Relay Therapeutics, Inc. · Filed Jul 8, 2026
Research Summary
AI-generated summary of this filing
Relay Therapeutics (RLAY) CFO Thomas Catinazzo Sells Shares
What Happened
- Thomas Catinazzo, Chief Financial Officer of Relay Therapeutics (RLAY), sold 17,717 shares on July 6, 2026. The weighted-average sale price reported was $18.69 per share, for total gross proceeds of approximately $331,131. This was a sale (not a purchase), and the transaction was reported as an open-market/private sale.
Key Details
- Transaction date: July 6, 2026; Form 4 filed July 8, 2026 (timely filing).
- Price range: trades executed at prices between $18.39 and $19.38; $18.69 is the weighted-average sale price (reporting person can provide per-trade breakdown on request).
- Shares disposed: 17,717 (all reported as sales).
- Shares owned after transaction: not specified in the excerpt provided; the filing notes include 9,807 shares underlying restricted stock units.
- Notable footnotes: transaction executed under a Rule 10b5-1 trading plan adopted October 30, 2025 (preplanned trades).
Context
- Sales under a 10b5-1 plan are typically prearranged and do not necessarily indicate a change in the insider’s view of the company. This was a routine insider sale rather than an acquisition or option exercise.
Insider Transaction Report
Form 4
Catinazzo Thomas
Chief Financial Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-07-06$18.69/sh−17,717$331,131→ 159,744 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- [F2]This transaction was executed in multiple trades at prices ranging from $18.39 to $19.38. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F3]Includes 9,807 shares underlying restricted stock units.
Signature
/s/ Soo-Yeun Lim, as Attorney-in-Fact|2026-07-08